NJ-CARAVAN-BIOLOGIX
15.9.2022 16:01:38 CEST | Business Wire | Press release
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini-CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Forrester Announces The Agenda For Its 2026 CX Events To Help Address The Challenges AI Can’t Handle Alone2.3.2026 15:30:00 CET | Press release
The global event series will bring together customer experience, marketing, and digital business leaders at CX Forum East, CX Forum West, and CX Summit EMEA Forrester (Nasdaq: FORR) today announced the agenda for its global customer experience (CX) event series: CX Summit EMEA, being held in Amsterdam, June 8–10, 2026; CX Forum East, being held in New York City, June 16–17, 2026; and CX Forum West, being held in San Francisco, June 29–30, 2026. Today, CX, marketing, and digital business leaders are under mounting pressure to leverage AI to architect smarter end-to-end customer journeys, automate service, operationalize AI agents, and deliver true personalization at scale — all while consumer trust is at an all-time low. While AI is promising to raise the bar for speed and efficiency, beneath every customer experience is a foundation that AI alone can’t build. To forge trust, organizations need to embed human creativity, context, customer identity, and quality data into every customer i
Incode First to Achieve iBeta’s Highest Level of Independent Identity Security Testing on Both iOS and Android With 0% Error Rate2.3.2026 15:00:00 CET | Press release
Records 0% APCER and 0% BPCER under ISO/IEC 30107-3 Level 3 testing - delivered through a fully passive single-selfie experience Incode Technologies, Inc., the global leader in identity security and fraud prevention, today announced that iBeta PAD testing confirmed Incode’s face liveness technology achieves Level 3 Presentation Attack Detection (PAD) conformance under ISO/IEC 30107-3. "We are the first company to independently achieve iBeta Level 3 conformance on both iOS and Android – with zero errors and without adding friction to users," said Ricardo Amper, Founder & CEO at Incode. "That combination matters. It proves we can meet the highest bar for liveness assurance while keeping onboarding fast and easy, even in regulated and high-risk environments." Face liveness technology is used in digital onboarding and authentication to confirm a real, live person is present during a selfie capture – not a printed photo, video replay, mask, or other spoofing attempt. It enables organization
Safe Software Expands its FME Platform with MCP2.3.2026 15:00:00 CET | Press release
FME embraces MCP in two ways: connecting to more systems than ever, while bringing the power of AI to its entire data ecosystem Today, Safe Software (Safe), the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, announced that Model Context Protocol (MCP) capabilities are coming soon to its FME Platform. This update expands what organizations can do with their existing data and workflows. As organizations move AI from experimentation to production they face growing challenges around context management, interoperability, and security. MCP provides a standardized way for AI, agents and other systems to interact with external systems, such as databases, internal tools, and APIs, without hard-coding integrations. “Adding MCP to the FME Platform is an important step in our All-Data, Any-AI mission,” said Don Murray, CEO of Safe Software. “With MCP, our customers can adopt new AI models without rebuilding integrations. By extending F
Smartly Announces Amazon DSP Integration to Extend Intelligent Creative and Campaign Management to Connected TV2.3.2026 14:59:00 CET | Press release
Smartly’s integration with Amazon DSP unifies social and CTV campaigns, pairing intelligent creative with full-funnel activations and reporting across Amazon's premium streaming inventory Smartly announced today an integration with Amazon DSP that enables advertisers to extend their Smartly video campaigns to Amazon's premium CTV inventory, including Prime Video and Fire TV, and third-party publisher inventory. The new integration addresses growing market demand as CTV investment accelerates, with nearly 70% of marketers1 planning to increase streaming budgets over the next year while seeking more personalization, agility, and measurable outcomes from their campaigns. The Smartly integration with Amazon DSP is available globally, with additional features rolling out later in 2026. The integration brings streaming TV activation into advertisers' existing workflows in Smartly through three core capabilities. Smartly enables AI-powered creative optimization and personalization from social
Lone Star Funds Completes Sale of SPX FLOW to ITT Inc.2.3.2026 14:50:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XI, L.P. has successfully completed the sale of SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of ITT common stock. SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. Since acquiring SPX FLOW, Lone Star has worked alongside the company’s leaders to further develop its operations and product capabilities. Together, Lone Star and SPX FLOW improved the company’s commercial organization and executed growth initiatives that have positioned it for long-term success. “We are pleased to reach this
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom